Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265953 | 0.78 | CTSC (0.34) | CTSC | |
| SCHEMBL295040 | 0.78 | CTSC (0.34) | CTSC | |
| SCHEMBL294800 | 0.75 | — | — | |
| SCHEMBL22053991 | 0.75 | — | — | |
| SCHEMBL12326839 | 0.75 | — | — | |
| SCHEMBL24682132 | 0.74 | — | — | |
| SCHEMBL24682121 | 0.73 | — | — | |
| Alcohol SCHEMBL28206180 | 0.73 | CTSC (0.34) | CTSC | |
| SCHEMBL4684131 | 0.72 | PRCP (0.42) | CTSC | |
| SCHEMBL18664467 | 0.72 | PRCP (0.42) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470844-B2 | Imidazoacridinone derivative compounds and methods for their use | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2013-06-25 | — | — | US | disclosed |
| US-20100137351-A1 | Imidazoacridinone derivative compounds and methods for their use | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-06-03 | — | — | US | disclosed |
| US-20080274998-A1 | Disaccharide Molecules and Derivatives Thereof and Methods of Using Same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2008-11-06 | — | — | US | disclosed |
| WO-2008021745-A2 | HEPATITIS C VIRUS ENTRY INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2006002022-A2 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA | IMMUSOL INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005076743-A2 | DISACCHARIDE MOLECULES AND DERIVATIVES THEREOF AND METHODS OF USING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-08-25 | — | — | WO | disclosed |
| US-20040102629-A1 | Thioquinazolinone derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG. (DE) | 2004-05-27 | — | — | US | disclosed |
| US-6677452-B1 | PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE | LION BIOSCIENCE AG (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6660858-B2 | Made by reacting a benzoxazole with a leaving group at the 2 position and a diamine of given formula | LION BIOSCIENCE AG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-6515122-B1 | The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. | LION BIOSCIENCE AG (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG (DE) | 2002-10-31 | — | — | US | disclosed |
| US-6458789-B1 | ANTICOAGULENTS, ANTIHISTAMINES, ANTISEPTICS, ANTIARRHYTHMICS AND ANTIRHEUMATICS | LION BIOSCIENCE AG (DE) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274998-A1 | Disaccharide Molecules and Derivatives Thereof and Methods of Using Same | MSN, MAN2B2, MASP2 | CTSC 934/4885 |
| US-20100137351-A1 | Imidazoacridinone derivative compounds and methods for their use | IDH3A, IDH3B, ABL1 | CTSC 2561/4885 |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | BCAT2, IL4I1, BCAT1 | CTSC 3071/4885 |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | CXCR2, BICRA, CXCR1 | CTSC 2297/4885 |
| US-20040102629-A1 | Thioquinazolinone derivatives and combinatorial libraries thereof | TTI1, RPS4Y1, TSNAX | CTSC 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.